Israel Business Currents
SEE OTHER BRANDS

Fresh news on business and economy in Israel

Israel Business Currents: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Israel Business Currents.

Press releases published on May 5, 2025

סקוורטולק משיקה פלטפורמת מוקדים טלפוניים חדשה - הצעד הראשון בחזון הנועז לאוטומציית מכירות

סקוורטולק משיקה פלטפורמת מוקדים טלפוניים חדשה - הצעד הראשון בחזון הנועז לאוטומציית מכירות

ספק פתרונות תקשורת בענן בעל הדירוג הגבוה ביותר, משיק תוכנה חדשה שמשנה את הדרך שבה צוותי מכירות יוצרים קשר עם לידים, ממירים אותם ללקוחות וצומחים JERUSALEM, ISRAEL, May 5, 2025 /⁨EINPresswire.com⁩/ -- סקוורטולק, פתרון למוקדים מבוסס ענן שנבנה במיוחד עבור …

Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis

Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis

Ramat Gan, Israel, May 05, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory diseases, today announced that …

Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)

Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)

The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April 30, 2025 SELARSDI is approved for all indications …

Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)

Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)

The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April 30, 2025 SELARSDI is approved for all indications …

Kamada Announces Launch of a Comprehensive Post-Marketing Research Program for CYTOGAM®

Kamada Announces Launch of a Comprehensive Post-Marketing Research Program for CYTOGAM®

Program Aimed at Generating Key Data in Support of the Benefits of CYTOGAM® in the Management of Cytomegalovirus (CMV) in Solid Organ Transplantation A Total of 10 Studies will be Conducted in Collaboration with Leading U.S. Physicians, Primarily as …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service